Sepax Scoops up ￥200M in a Series C Funding Round

(VCBeat) Mar. 8, 2021 -- Recently, Suzhou Sepax Technologies, Inc. ("Suzhou Sepax") announced the close of a Series C investment round of over 200 million RMB, with participation from China Life Healthcare Fund and Fosun. The investment will consolidate Sepax's position as a leader in the field of chromatography in the separation of biomacromolecules, and improve the R&D, production, and operation capabilities in analytical chromatography, industrial purification, medical diagnostics and other businesses.

Since 2002, Sepax, a Delaware US-based company, has been providing cutting-edge products and services for liquid chromatography (LC). Sepax specializes in the development and manufacture of LC analytical, preparative and process separation & purification columns, bulk resins, and systems in a wide range of modalities, such as SEC, IEX, HIC, Affinity, and RP. Sepax also provides LC services, including analytical testing, method optimization, purification, custom resin development, and ligand immobilization.

In 2009, Suzhou Sepax was established in Suzhou Industrial Park, focusing on the development and operation of Sepax in the Chinese market, focusing on creating a Chinese national industrial brand in the field of chromatography technology.

In 2017, Yangzhou Sepax was established, focusing on the large-scale production of chromatographic media. By the end of 2020, the production base has been formally put into operation, with a total of four production lines built in the first phase, with an annual output of 100,000 liters.

This financing will support Sepax to play a more important role in the security, cost control, and separation and purification technology development of China's biopharmaceutical supply chain.

Established in June 2016 and registered in Shanghai Free Trade Zone, China Life Private Equity Investment is a leading professional investment platform as a subsidiary of China Life. In November 2016, China Life Private Equity Investment launched the China Life Healthcare Fund as a leading flagship PE fund in China's healthcare industry. It was also among the first PE funds sponsored by insurance capital upon approval by CIRC.

Fosun's investment in Suzhou Sepax is jointly led and completed by its USD Industrial Fund and Fosun Capital.

Fosun Capital operates as a private equity firm. The company focuses on advanced manufacturing, healthcare, internet, lifestyle, resources, energy and environment, and real estate sectors. 

 Relying on Fosun and connecting Fosun and its partners, Fosun USD Industrial Fund focuses on the big health, consumer and technology tracks.